CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Therapeutic Plasma Exchange (TPE)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1727 PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test) Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Does Therapeutic Plasma Exchange Have A Role in Resistant Cytokine Storm State Of COVID-19 Infection?

This research is planned to illustrate the efficacy of Therapeutic Plasma Exchange (TPE) treatment in COVID-19 patients with resistant cytokine storm state.

NCT04457349 COVID 19 Procedure: Therapeutic Plasma Exchange (TPE)

Primary Outcomes

Description: Number of patients deaths of the total of patients included

Measure: mortality

Time: 28 day

Secondary Outcomes

Description: to calculate the mean time with oxygen therapy

Measure: the mean time with oxygen therapy

Time: through study completion, and average of 1 month

Description: to calculate the mean time with Non-invasive mechanical ventilation

Measure: the mean time with Non-invasive mechanical ventilation

Time: through study completion, and average of 1 month

Description: to calculate the mean time of intubation

Measure: the mean time of intubation

Time: through study completion, and average of 1 month

Description: To calculate the mean of PaO2/FiO2

Measure: respiratory function parameters

Time: through study completion, and average of 1 month

Description: To calculate the mean of levels of oxygen saturation

Measure: respiratory function parameters

Time: through study completion, and average of 1 month

Description: to evaluate the lung extension of pneumonia

Measure: radiological lung extension

Time: through study completion, and average of 1 month

Description: Days of hospitalization in survivors and/or days at ICU throughout the study

Measure: mean duration of hospitalization and ICU use

Time: through study completion, and average of 1 month

Description: Percentage of patients with dialysis

Measure: the requirement of additional organ support

Time: through study completion, and average of 1 month

Description: To evaluate the effect of TPE on the serum levels of inflammatory markers

Measure: the levels of IL-6

Time: through study completion, and average of 1 month

Description: To calculate the number of adverse events in patients with COVID-19 treated with TPE

Measure: Incidence of adverse events

Time: through study completion, and average of 1 month

Description: To evaluate the time to RT-PCR virus negativity

Measure: time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity

Time: through study completion, and average of 1 month

Description: To evaluate the effect of TPE on the serum levels of inflammatory markers

Measure: the levels of CRP

Time: through study completion, and average of 1 month

Description: To evaluate the effect of TPE on the serum levels of inflammatory markers

Measure: the levels of procalcitonin (PCT)

Time: through study completion, and average of 1 month

Description: To evaluate the effect of TPE on the serum levels of inflammatory markers

Measure: levels of D-dimer

Time: through study completion, and average of 1 month

Description: To evaluate the effect of TPE on the serum levels of inflammatory markers

Measure: levels of ferritin

Time: through study completion, and average of 1 month


No related HPO nodes (Using clinical trials)